Abbvie Inc. vs Merck & Co., Inc.
ABBV vs MRK — side-by-side comparison from reported financials. ABBV leads 6, MRK leads 4 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Merck & Co., Inc.
MRK · Healthcare
$146.33+2.77%Mixed
| Metric | ABBV | MRK |
|---|---|---|
| Price | $276.43 | $146.33 |
| Market cap | $488B | $361B |
| Revenue (TTM) | $64.4B | $66.6B |
| Revenue growth | +1.8% | +3.1% |
| Net margin | 9.8% | 4.8% |
| Free cash flow | $18.2B | $16.1B |
| Net cash (debt) | ($56.2B) | ($34.8B) |
| 1-year price return | +19.8% | +67.2% |
| P/E | 77.4 | 113.2 |
| P/E vs own history (cheap-side %) | 23% | 7% |
| Dividend yield | 2.45% | 2.31% |
| Return on equity | 96% | 7% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 75,000 |
Full résumé-style profiles: ABBV CV · MRK CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.